Literature DB >> 7220430

Isolated limb perfusion for malignant melanoma.

R D Rosin, G Westbury.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7220430

Source DB:  PubMed          Journal:  Practitioner        ISSN: 0032-6518


× No keyword cloud information.
  6 in total

1.  Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 2.  Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.

Authors:  A M Eggermont; T L ten Hagen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

3.  Melphalan concentration dependent plasma protein binding in healthy humans and rats.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Hyperthermic isolated limb perfusion for malignant melanoma: response and survival.

Authors:  P J Bryant; G A Balderson; P Mead; W S Egerton
Journal:  World J Surg       Date:  1995 May-Jun       Impact factor: 3.352

5.  The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.

Authors:  R N Scott; D J Kerr; R Blackie; J Hughes; G Burnside; R M MacKie; D S Byrne; A J McKay
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

6.  Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.

Authors:  M A Cornbleet; T J McElwain; P J Kumar; J Filshie; P Selby; R L Carter; D W Hedley; M L Clark; J L Millar
Journal:  Br J Cancer       Date:  1983-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.